Comparative Pharmacology
Head-to-head clinical analysis: LIQUAMAR versus PRADAXA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIQUAMAR versus PRADAXA.
LIQUAMAR vs PRADAXA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Liquamar (phenprocoumon) is a vitamin K antagonist that inhibits the synthesis of vitamin K-dependent clotting factors II, VII, IX, and X in the liver by blocking the reduction of vitamin K to its active hydroquinone form.
Direct thrombin inhibitor; binds reversibly to the active site of thrombin, preventing fibrinogen cleavage and subsequent thrombus formation.
Initial: 0.5-1 mg/kg IV (not to exceed 2 mg). Maintenance: 0.5-2 mg IV q8-12h based on INR.
150 mg orally twice daily; for patients with CrCl 15-30 mL/min, 75 mg orally twice daily.
None Documented
None Documented
The terminal elimination half-life of phenprocoumon is approximately 5 to 7 days (range 3-10 days). This long half-life results in sustained anticoagulant effect over days, requiring careful monitoring and dose adjustments.
12–17 hours (terminal); prolonged to 18–35 hours in severe renal impairment (CrCl <30 mL/min); supports twice-daily dosing
Phenprocoumon is excreted primarily via renal elimination as metabolites (approximately 60-70% of the dose), with about 20% excreted in feces via biliary elimination. Less than 1% is excreted unchanged in urine.
Renal (80% unchanged); fecal/biliary (20% as inactive metabolites via P-glycoprotein-mediated secretion)
Category C
Category C
Anticoagulant
Anticoagulant